Search Results for: transdifferentiation

Janet Rossant, ISSCR President, on her goals, cloning, non-compliant clinics, iPS cells, and future of field

New ISSCR President, Dr. Janet Rossant, kindly agreed to do an interview with me focused on the future of ISSCR, her plans for her tenure, and some key issues in the field. Dr. Rossant is Chief of Research at The Hospital for Sick Children in Toronto. 1. The stem cell arena is a very rapidly changing one […]

Janet Rossant, ISSCR President, on her goals, cloning, non-compliant clinics, iPS cells, and future of field Read More »

Delightful overview of ISSCR 2013 by guest blogger Dr. Susan Lim

This is a guest post on ISSCR 2013. By Dr. Susan Lim A record 4100 delegates attended the 11th Annual Meeting of the International Society for Stem Cell Research (ISSCR), held at the Convention and Exhibition Center in Boston from 12-15 June 2013. Co-sponsored by the Harvard Stem Cell Institute, the Meeting featured 7 Plenary

Delightful overview of ISSCR 2013 by guest blogger Dr. Susan Lim Read More »

Interview with Gary Rabin of Advanced Cell Technology (ACT)

Gary-Rabin-headshot-formatted-5.25

One of the more exciting stem cell biotechs out there today is Advanced Cell Technology (ACT). At this time ACT has the only two ES cell-based FDA-approved clinical trials ongoing and so far they have looked quite promising in terms of preliminary safety data. However, ACT has much more in the pipeline including potentially iPS

Interview with Gary Rabin of Advanced Cell Technology (ACT) Read More »

Interview with NeoStem CEO Robin Smith Part 2: VSEL, ES cells, and iPS cells

I recently did a Q&A interview with NeoStem CEO Dr. Robin Smith. I posted Part 1 of that interview a few days ago here. Now we have part two focused on VSEL, ES cells, and iPS cells. PK: I frequently have readers of my blog ask questions about VSEL. They seem puzzled and unsure of

Interview with NeoStem CEO Robin Smith Part 2: VSEL, ES cells, and iPS cells Read More »

Predictions for the stem cell field for 2013: but first how did I do predicting for 2012?

Every year I make predictions about what the following year will bring us in the stem cell field. For example, last year I made some predictions for 2012 and I shortly will do a post on my predictions for 2013. First, how did I do with my predictions for this year, which I made in

Predictions for the stem cell field for 2013: but first how did I do predicting for 2012? Read More »

What are the best iPS cell papers so far?

ipscellpapers

What are the most important iPS cell papers so far? 1) Yamanaka’s first paper on mouse iPS cells. Revolutionary. Intriguing perspectives presented in day 1 of the iPS cell field. Interesting statements such as Myc is required. Also take a look at those other reprogramming factors that he tested…there’s a tremendous amount there, largely unexamined.

What are the best iPS cell papers so far? Read More »

Stem cell predictions for 2012: Science, CIRM, ACT, trends

stem-cell-predictions

Each year at this time I start thinking about what the next year will bring for the stem cell field and make predictions. This year is no different and I’ve been pondering what 2012 has in store for us.  You can read my predictions for 2011 here and see how I fared. Not too bad, but overly optimistic

Stem cell predictions for 2012: Science, CIRM, ACT, trends Read More »

Ian Wilmut, Dolly’s dad, says dump hESC? What does this mean?

Ian-Wilmut

Sometimes a top scientist makes news with a quote on research and that happened with Ian Wilmut recently on stem cells. Move away from research on human ES cells (hESC) in favor of very new and still largely unclear trans-differentiation technology? I say, no way. But, Bradley Fikes of the North County Times has reported

Ian Wilmut, Dolly’s dad, says dump hESC? What does this mean? Read More »

The New Scientist goes after ES cells with strange opinion piece

What the heck happened to The New Scientist? An anti-embryonic stem cell piece they just recently published was an exercise in weird, moral obfuscation. Quite a few scientists and policy makers are fairly regular readers of The New Scientist. They might start reconsidering how they want to spend that $99/year. Why not use it to

The New Scientist goes after ES cells with strange opinion piece Read More »